InSphero announced the acquisition of PhenoVista Biosciences, Inc., in a move designed to expand its capabilities in advanced 3D cell-based assays, high-content imaging, and predictive in vitro modeling for drug discovery and toxicology research.
The acquisition combines PhenoVista’s expertise in high-content imaging, phenotypic analysis, and assay development with InSphero’s scalable 3D biology platforms, predictive in vitro models, and AkuraFlow microphysiological systems. The companies said the combined organization aims to accelerate the adoption of more predictive, human-relevant drug discovery and toxicology workflows across the pharmaceutical and biotechnology industries.
PhenoVista has built a reputation for providing image-based assay development, cellular analysis, and screening solutions to pharmaceutical and biotech customers. Through the acquisition, the company will gain access to InSphero’s global commercial infrastructure, complementary biological platforms, and expanded operational resources.
The companies said the combination is expected to create opportunities across oncology, fibrosis, neuroscience, and safety assessment research. Customers are expected to benefit from integrated workflows that combine 3D biology, high-content imaging, and AI-enabled analytics to generate more predictive datasets earlier in the drug discovery process.
InSphero also noted that recent momentum behind New Approach Methodologies in the United States, including support from the U.S. Food and Drug Administration and the National Institutes of Health, is helping accelerate the adoption of human-relevant in vitro technologies.
The companies said the expanded organization will enable faster turnaround times, closer customer collaboration, and broader access to advanced NAMs technologies in the growing in vitro market.
KEY QUOTES:
“The timing of this acquisition is particularly exciting given the accelerating momentum behind New Approach Methodologies in the United States. Recent policy initiatives and guidance from the U.S. Food and Drug Administration and growing investment support from the National Institutes of Health are creating a strong foundation for the broader adoption of human-relevant in vitro technologies. Together with PhenoVista, we are exceptionally well positioned to support this transition with scalable, industry-ready solutions.”
Jan Lichtenberg, CEO And Co-founder, InSphero AG
“Joining forces with InSphero represents a highly exciting opportunity for PhenoVista, our employees, and our customers. Both organizations share a strong commitment to advancing drug discovery through innovative assay technologies, advanced analytics, and artificial intelligence-driven approaches. By combining PhenoVista’s strengths in high-content imaging and assay development with InSphero’s leadership in scalable 3D biology and predictive in vitro models, we can deliver even greater scientific value and broader capabilities to customers worldwide.”
James G. Evans, PhenoVista Biosciences
